Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
3.
Am J Obstet Gynecol ; 229(1): 23-32.e3, 2023 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-36539027

RESUMO

OBJECTIVE: This meta-analysis was conducted to (1) assess the quantity and dose of perioperatively dispensed opioids for benign hysterectomy by procedure route and (2) identify the predictors of persistent opioid use after the procedure. DATA SOURCES: PubMed, Web of Science, and Embase were systematically searched from study inception to 25 March 2022. STUDY ELIGIBILITY CRITERIA: Studies reporting data on opioid dispensing among patients undergoing benign hysterectomy were considered eligible. The primary outcome was the dosage of opioids dispensed perioperatively (from 30 preoperative days to 21 postoperative days). The secondary outcome was the predictors of persistent opioid use after benign hysterectomy (from 3 months to 3 years postoperatively). Total opioid dispensing was measured in morphine milligram equivalents units. METHODS: The random-effects model was used to pool the mean differences or odds ratios and the corresponding 95% confidence intervals. RESULTS: A total of 8 studies presenting data on 377,569 women undergoing benign hysterectomy were included. Of these women, 83% (95% confidence interval, 81-84) were dispensed opioids during the perioperative period. The average amount of perioperatively dispensed opioids was 143.5 morphine milligram equivalents (95% confidence interval, 40-247). Women undergoing vaginal hysterectomy were dispensed a significantly lower amount of opioids than those undergoing laparoscopic or abdominal hysterectomies. The overall rate of persistent opioid use after benign hysterectomy was 5% (95% confidence interval, 2-8). Younger patient age (odds ratio, 1.38; 95% confidence interval, 1.17-1.63), smoking history (odds ratio, 1.87; 95% confidence interval, 1.67-2.10), alcohol use (odds ratio, 3.16; 95% confidence interval, 2.34-4.27), back pain (odds ratio, 1.50; 95% confidence interval, 1.10-2.05), and fibromyalgia (odds ratio, 1.60; 95% confidence interval, 1.39-1.83) were significantly associated with a higher risk of persistent opioid use after benign hysterectomy. However, there was no significant effect of hysterectomy route and operative complexity on persistent opioid use postoperatively. CONCLUSION: Perioperative opioid dispensing was significantly dependent on the route of hysterectomy, with the lowest dispensed morphine milligram equivalents of opioids for vaginal hysterectomy and the highest for abdominal hysterectomy. Nevertheless, hysterectomy route did not significantly predict persistent opioid use postoperatively, whereas younger age, smoking, alcohol use, back pain, and fibromyalgia were significantly associated with persistent opioid use.


Assuntos
Fibromialgia , Transtornos Relacionados ao Uso de Opioides , Humanos , Feminino , Analgésicos Opioides/uso terapêutico , Fibromialgia/tratamento farmacológico , Dor Pós-Operatória/tratamento farmacológico , Histerectomia/métodos , Transtornos Relacionados ao Uso de Opioides/epidemiologia , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Derivados da Morfina
4.
Reprod Sci ; 28(8): 2129-2135, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-33599949

RESUMO

Ovarian tissue cryopreservation (OTC) is an accepted method of fertility preservation. However, OTC is not standardized and many variations exist in the freezing strategy, tissue processing, and surgical approach. In this pilot study, we used a sheep model to compare slow freezing versus vitrification techniques, as well as the feasibility of processing ovarian tissue into a hyaluronan suspension of small ovarian units. Twelve ovaries were harvested from six female ewes. Paired tissues from each animal were assigned to different treatments and underwent freezing, thawing, autotransplantation, and second-look surgery, for a total of 18 surgical procedures and 3 measured time points. Treatments included whole tissue strips versus gel suspension and slow freezing versus vitrification. At each of the time points, tissue viability was measured by immunohistochemical analysis of CD31 and cleaved caspase-3 (CCASP3). CD31 and CCASP3 expression levels were equivalent between slow freezing and vitrification, and between whole ovarian tissue strips and gel suspension of fragmented ovarian tissue, at all time points. These preliminary data using a sheep model suggest that ovarian tissue is robust and likely to be minimally affected by aggressive fragmentation using a hyaluronan suspension. Furthermore, we provide evidence in support of vitrification as a viable option in OTC. Hyaluronan suspension of ovarian cortical fragments is novel and may represent a desirable method for reimplantation of frozen-thawed ovarian tissue in patients where occult malignant cells are a concern.


Assuntos
Criopreservação/métodos , Preservação da Fertilidade/métodos , Ovário/transplante , Animais , Feminino , Ovinos , Sobrevivência de Tecidos , Transplante Autólogo
5.
Fertil Steril ; 109(5): 941, 2018 05.
Artigo em Inglês | MEDLINE | ID: mdl-29778393

RESUMO

OBJECTIVE: To describe and demonstrate ovarian tissue cryopreservation (OTC) as an emerging fertility preservation technique DESIGN: Video presentation. SETTING: University hospital. PATIENT(S): A 6 year-old female patient diagnosed with aplastic anemia with plan for bone marrow transplantation underwent laparoscopic unilateral oophorectomy in conjunction with surgical procedure for port placement by the pediatric surgeon, followed by cryopreservation of ovarian tissue. INTERVENTION(S): Laparoscopic unilateral oophorectomy followed by ovarian decortication in the operating room, and ovarian tissue freezing prior to undergoing bone marrow transplantation. MAIN OUTCOME MEASURE(S): To present principle surgical techniques of ovarian tissue harvesting prior to OTC in pediatric patients, and different surgical techniques for ovarian auto-transplantation of cryobanked ovarian tissue after completion of gonadotoxic treatment and when the patient is ready to conceive. RESULT(S): This video demonstrates the detailed surgical technique for ovarian tissue harvesting. This harvesting can be performed laparoscopically or via mini-laparotomy and can involve a complete oophorectomy versus removing a portion of the ovary (a procedure also known as ovarian decortication). CONCLUSION(S): In the prepubertal child, due to the small size of the ovaries, we recommend oophorectomy rather than decortication owing to the small size of prepubertal gonadal tissue. Many young cancer patients can be offered the option of ovarian tissue freezing. This tissue contains immature primordial follicles that can be stored. OTC requires surgical ovarian harvesting followed by cryopreservation of strips of ovarian tissue. The increased number of eggs in prepubertal children underscores the fact that smaller ovarian size in this population does not preclude OTC. At this time, ovarian auto-transplantation is the only option to utilize this stored tissue for fertility preservation. OTC is a relatively new procedure within the area of ART. The overall data from OTC is reassuring and further suggests that cryopreservation of ovarian tissue has the potential to become an established fertility preservation method in the near future.


Assuntos
Anemia Aplástica/cirurgia , Criopreservação/métodos , Preservação da Fertilidade/métodos , Neoplasias/cirurgia , Ovariectomia/métodos , Anemia Aplástica/complicações , Criança , Feminino , Humanos , Neoplasias/complicações , Neoplasias/diagnóstico
6.
Fertil Steril ; 107(4): e15, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28238491

RESUMO

OBJECTIVE: To describe and demonstrate a novel surgical method for laparoscopic ovarian transposition. In this video, we present a unique minimally invasive technique for transposing the ovaries, whereby the ovary is tunneled through the peritoneum. DESIGN: Video presentation of clinical article. The video uses animations and a surgical case to demonstrate the detailed surgical technique for laparoscopic ovarian transposition with a unique feature. Institutional review board approval was not required for this video presentation. Institutional review board approval is not required at the Cleveland Clinic for a case report of a single patient. SETTING: Teaching University. PATIENT(S): A 29-year-old female patient diagnosed with rectal cancer. INTERVENTION(S): The patient underwent laparoscopic ovarian transposition followed by ovarian decortication for ovarian tissue freezing of the contralateral ovary, both performed in one laparoscopic surgery, before further chemotherapy and radiation. MAIN OUTCOME MEASURE(S): Value and feasibility of laparoscopic ovarian transposition using the unique feature of ovarian tunneling in maintaining the retroperitoneal location of the ovarian vessels and potentially preserving ovarian blood supply. RESULT(S): Creating a retroperitoneal tunnel for passing the ovary through is a feasible and effective technique, while performing laparoscopic ovarian transposition that can be performed in order to prevent the ovarian vessels from taking a sharp turn into the pelvic cavity and thereby preventing alteration of ovarian blood flow. CONCLUSION(S): Ovarian transposition is a great surgical option for fertility preservation in reproductive-aged women before they undergo gonadotoxic pelvic or craniospinal radiation. This surgical procedure is not a beneficial option for those patients receiving concomitant gonadotoxic chemotherapy. Ovarian transposition can be performed using different surgical techniques, including laparotomy and laparoscopy. Laparoscopic ovarian transposition is the preferred surgical technique described in the literature, because it is associated with more rapid recovery and less postoperative pain. This technique has been reported to have a success rate of 88.6% for preservation of ovarian function, as documented by measuring the gonadotropin levels after cancer treatment. Ovarian transposition is considered to be a safe and effective surgical option to prevent from premature ovarian failure and to optimize preservation of fertility.


Assuntos
Quimiorradioterapia/efeitos adversos , Preservação da Fertilidade/métodos , Fertilidade , Infertilidade/terapia , Laparoscopia , Ovário/irrigação sanguínea , Ovário/cirurgia , Peritônio/cirurgia , Neoplasias Retais/terapia , Adulto , Criopreservação , Feminino , Fertilidade/efeitos dos fármacos , Fertilidade/efeitos da radiação , Humanos , Infertilidade/etiologia , Infertilidade/fisiopatologia , Neoplasias Retais/patologia , Resultado do Tratamento
7.
Robot Surg ; 4: 7-18, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-30697559

RESUMO

Robotic-assisted surgery has seen a rapid development and integration in the field of gynecology. Since the approval of the use of robot for gynecological surgery and considering its several advantages over conventional laparoscopy, it has been widely incorporated especially in the field of reproductive surgery. Uterine fibroids are the most common benign tumors of the female reproductive tract. Many reproductive-aged women with this condition demand uterine-sparing surgery to preserve their fertility. Myomectomy, the surgical excision of uterine fibroids, remains the only surgical management option for fibroids that entails preservation of fertility. In this review, we focus on the role of robotic-assisted laparoscopic myomectomy and its current status, in comparison with other alternative approaches for myomectomy, including open, hysteroscopic, and traditional laparoscopic techniques. Several different surgical techniques have been demonstrated for robotic myomectomy. This review endeavors to share and describe our surgical experience of using the standard laparoscopic equipment for robotic-assisted myomectomy, together with the da Vinci Robot system. For the ideal surgical candidate, robotic-assisted myomectomy is a safe minimally invasive surgical procedure that can be offered as an alternative to open surgery. The advantages of using the robot system compared to open myomectomy include a shorter length of hospital stay, less postoperative pain and analgesic use, faster return to normal activities, more rapid return of the bowel function, and enhanced cosmetic results due to smaller skin incision sizes. Some of the disadvantages of this technique include high costs of the robotic surgical system and equipment, the steep learning curve of this novel system, and prolonged operative and anesthesia times. Robotic technology is a novel and innovative minimally invasive approach with demonstrated feasibility in gynecological and reproductive surgery. This technology is expected to take the lead in gynecological surgery in the upcoming decade.

8.
Clin Obstet Gynecol ; 59(1): 30-52, 2016 03.
Artigo em Inglês | MEDLINE | ID: mdl-26756261

RESUMO

Fibroids are the most common tumor of the female reproductive tract, but approved medical treatments are limited. Patients demand uterine-sparing treatments which preserve fertility and avoid surgery. We systematically reviewed PubMed and Cochrane databases from January 1985 to November 2015 for evidence-based medical therapies for fibroids in the context of disease prevention, treatment of early disease, treatment of symptomatic disease, and preoperative management. We identified 2182 studies, of which 52 studies met inclusion and exclusion criteria. Published data affirm the efficacy of multiple agents, which are promising avenues for the development of medical alternatives to surgery.


Assuntos
Androgênios/uso terapêutico , Inibidores da Aromatase/uso terapêutico , Anticoncepcionais Femininos/uso terapêutico , Hormônio Liberador de Gonadotropina/agonistas , Antagonistas de Hormônios/uso terapêutico , Leiomioma/tratamento farmacológico , Extratos Vegetais/uso terapêutico , Neoplasias Uterinas/tratamento farmacológico , Anticoncepcionais Orais Combinados/uso terapêutico , Curcumina , Preparações de Ação Retardada , Medicamentos de Ervas Chinesas/uso terapêutico , Estradiol/análogos & derivados , Estradiol/uso terapêutico , Estrenos/uso terapêutico , Antagonistas do Receptor de Estrogênio/uso terapêutico , Medicina Baseada em Evidências , Feminino , Fulvestranto , Hormônio Liberador de Gonadotropina/antagonistas & inibidores , Humanos , Dispositivos Intrauterinos Medicados , Leiomioma/prevenção & controle , Levanogestrel/uso terapêutico , Acetato de Medroxiprogesterona/uso terapêutico , Mifepristona/uso terapêutico , Terapia Neoadjuvante , Norpregnadienos/uso terapêutico , Oximas/uso terapêutico , Receptores de Progesterona/antagonistas & inibidores , Moduladores Seletivos de Receptor Estrogênico/uso terapêutico , Chá , Miomectomia Uterina , Neoplasias Uterinas/prevenção & controle , Vitamina D/uso terapêutico , Vitaminas/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA